Eledon Pharmaceuticals (ELDN)
(Delayed Data from NSDQ)
$2.54 USD
+0.05 (2.01%)
Updated Sep 26, 2024 04:00 PM ET
4-Sell of 5 4
F Value A Growth C Momentum D VGM
Income Statements
Fiscal Year end for Eledon Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 43 | 88 | 37 | 18 | 16 |
Income After Depreciation & Amortization | -43 | -88 | -37 | -18 | -16 |
Non-Operating Income | 3 | 0 | 0 | -5 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -40 | -88 | -37 | -23 | -16 |
Income Taxes | 0 | 0 | -2 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -40 | -88 | -35 | -23 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -40 | -88 | -35 | -23 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -39 | -37 | -18 | -14 |
Depreciation & Amortization (Cash Flow) | 0 | 49 | 0 | 0 | 2 |
Income After Depreciation & Amortization | -43 | -88 | -37 | -18 | -16 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 24.62 | 14.29 | 14.82 | 1.45 | 0.66 |
Diluted EPS Before Non-Recurring Items | -1.64 | -2.75 | -2.33 | -10.82 | -21.58 |
Diluted Net EPS (GAAP) | -1.64 | -6.16 | -2.33 | -15.72 | -24.46 |
Fiscal Year end for Eledon Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 14.51 | 10.87 | 10.34 | 11.20 | 10.35 |
Income After SG&A, R&D, and Dept/Amort Expenses | -14.51 | -10.87 | -10.34 | -11.20 | -10.35 |
Non-Operating Income | -30.41 | 0.57 | 0.71 | 0.85 | 0.78 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -44.91 | -10.30 | -9.63 | -10.35 | -9.58 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -44.91 | -10.30 | -9.63 | -10.35 | -9.58 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -44.91 | -10.30 | -9.63 | -10.35 | -9.58 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 42.28 | 29.99 | 24.62 | 29.97 | 24.01 |
Diluted EPS Before Non-Recurring Items | -0.32 | -0.34 | -0.29 | -0.35 | -0.40 |
Diluted Net EPS (GAAP) | -1.06 | -0.34 | -0.14 | -0.35 | -0.40 |